Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O3OS
|
|||
| Former ID |
DNC001371
|
|||
| Drug Name |
SR141716A
|
|||
| Synonyms |
Riobant; Slimona; [3H]SR141716A; Acomplia (TN); Bethin (TN); Monaslim (TN); Remonabent (TN); Rimonabant [USAN:INN]; Rimoslim (TN); Riobant (TN); Riomont (TN); Slimona (TN); Zimulti (TN); Rimonabant (JAN/USAN/INN); 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; 5-(p-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Approved | [1], [2] | |
| Therapeutic Class |
Antiobesity Agents
|
|||
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H21Cl3N4O
|
|||
| Canonical SMILES |
CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
|
|||
| InChI |
1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
|
|||
| InChIKey |
JZCPYUJPEARBJL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 168273-06-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10233641, 10587968, 12014928, 14809274, 17395319, 26757994, 44434444, 47207392, 49689350, 50029120, 53787104, 56365488, 57299045, 57337879, 68530732, 75561655, 81041153, 85209313, 91615920, 92714061, 94569195, 99443236, 103178666, 103856306, 104373082, 113635232, 117886272, 125333755, 126592979, 126629680, 126655698, 126670698, 127344006, 127344007, 127344008, 128348432, 131301471, 131549355, 134337619, 134339398, 134340563, 135135276, 135650901, 135684000, 135697615, 136375412, 137001352, 137202776, 141966451, 144205753
|
|||
| ChEBI ID |
CHEBI:34967
|
|||
| ADReCS Drug ID | BADD_D01947 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [3], [4], [5] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007737) | |||
| REF 3 | Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. | |||
| REF 4 | The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004 Apr;113(8):1202-9. | |||
| REF 5 | Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol. 2001 May 11;419(2-3):191-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.